Related references
Note: Only part of the references are listed.Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma
Alison J. Moskowitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
Todd A. Fehniger et al.
BLOOD (2011)
Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma
Boris Boell et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma
Andreas Josting et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
Alison J. Moskowitz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions
Ling Lu et al.
MICROVASCULAR RESEARCH (2009)
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy
Joseph A. Blansfield et al.
CLINICAL CANCER RESEARCH (2008)
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
N. L. Bartlett et al.
ANNALS OF ONCOLOGY (2007)
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors
Scott D. Young et al.
CLINICAL CANCER RESEARCH (2006)
Circulating endothelial progenitor cells in multiple myeloma:: implications and significance
H Zhang et al.
BLOOD (2005)
Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro
PAJ Haslett et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels
M Colleoni et al.
ANNALS OF ONCOLOGY (2002)
Share Paper
